SCHEMBL21569719

SCHEMBL21569719

Cc1cc(Cl)c(S(=O)(=O)NCCc2ccccc2O)c(C)c1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.42
ALOX15 P16050 4/20 0.38
GAA P10253 3/20 0.38
HSD17B10 Q99714 3/20 0.38
ALDH1A1 P00352 2/20 0.38
PKM P14618 2/20 0.38
HTT P42858 1/20 0.38
MPO P05164 2/20 0.38
TSHR P16473 1/20 0.38
CPB1 P15086 1/20 0.37
MGAM O43451 1/20 0.36
ACLY P53396 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
HPGD P15428 2/20 0.36
POLB P06746 1/20 0.35
MCL1 Q07820 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31277145 0.80 MPO (0.41) L3MBTL1MPOMGAMACLYCA12
SCHEMBL21569715 0.80 MPO (0.41) L3MBTL1MPOMGAMACLYCA12
SCHEMBL21569711 0.80 MAPT (0.43) L3MBTL1MPOMGAM
SCHEMBL21569721 0.80 L3MBTL1 (0.55) L3MBTL1ALOX15GAAPKMMPO
SCHEMBL21569713 0.80 L3MBTL1 (0.66) L3MBTL1GAAHTTTSHRKMT2A
SCHEMBL21569714 0.79 L3MBTL1 (0.51) L3MBTL1GAAALDH1A1MPOMGAM
SCHEMBL21569716 0.77 L3MBTL1 (0.43) L3MBTL1ALOX15HSD17B10ALDH1A1PKM
SCHEMBL21550402 0.77 MGAM (0.41) L3MBTL1PKMHTTMPOMGAM
SCHEMBL31277013 0.77 MGAM (0.41) L3MBTL1PKMHTTMPOMGAM
SCHEMBL31277514 0.77 L3MBTL1 (0.43) L3MBTL1ALOX15HSD17B10ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US claimed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US claimed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US claimed
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 L3MBTL1 4858/4885ALOX15 999/4885GAA 411/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885ALOX15 1076/4885GAA 464/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 L3MBTL1 4838/4885ALOX15 1076/4885GAA 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.